What happened with IMCR today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Immunocore Holdings plc’s business centers on KIMMTRAK (tebentafusp), a medicine approved for adults with HLA-A*02:01-positive uveal melanoma, an eye cancer that cannot be surgically removed or has spread. Distributors and healthcare providers buy the medicine from Immunocore. KIMMTRAK supplies nearly all revenue, with the United States the largest market and Europe the next largest. A small group of customers accounts for most therapy sales.
Immunocore uses its own U.S. sales force alongside contracted commercial teams, and works with distribution partners including Medison and Er-Kim in other markets. It outsources manufacturing to companies including AGC Biologics and Simtra Biopharma Solutions. Sales depend on physicians prescribing KIMMTRAK, insurers and other payors covering treatment, and these partners maintaining supply and distribution.
The company also uses its ImmTAX platform to engineer medicines that recognize disease-related targets and activate or inhibit an immune response. It is developing candidates for cancer, infectious diseases and autoimmune diseases, but none of its other candidates is approved for sale. KIMMTRAK’s current approval is limited to its specified uveal melanoma use in approved markets; additional uses and other candidates require further regulatory approval.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Delcath Systems Inc competes for patients within Immunocore’s KIMMTRAK market by selling HEPZATO KIT in the United States, delivering chemotherapy directly to the liver for certain adults with unresectable uveal-melanoma liver metastases. HEPZATO KIT adoption is the commercial signal to watch alongside KIMMTRAK uptake.
Immatics N.V. challenges Immunocore in melanoma and PRAME-targeted cancer treatments: both develop medicines that use T-cell receptors to recognize cancer targets displayed by HLA molecules. Watch Immatics’ Phase 1/2 PRAME trial of a medicine that links those targets to T cells, a bispecific approach competing with Immunocore’s.
IDEAYA Biosciences, Inc. is developing darovasertib as an alternative approach to the uveal melanoma treated by Immunocore’s revenue-generating KIMMTRAK. Watch the expected 2026 results from its first-line metastatic uveal-melanoma registrational Phase 2/3 trial, while keeping the eligibility difference clear: that trial enrolls HLA-A*02:01-negative patients, whereas KIMMTRAK is approved for HLA-A*02:01-positive adults.
Replimune Group, Inc. competes with Immunocore’s marketed therapy and melanoma pipeline by developing cancer treatments that destroy tumors through oncolytic immunotherapy, including RP2 for uveal melanoma. Its potentially registration-enabling RP2 trial is the news to watch; Replimune had no approved products or product-sale revenue through the fiscal year ended March 31, 2026.
Iovance Biotherapeutics, Inc. competes in advanced melanoma, particularly against Immunocore’s cutaneous-melanoma pipeline rather than its uveal-melanoma drug KIMMTRAK. Iovance sells Amtagvi, a one-time treatment made by multiplying a patient’s tumor-infiltrating T cells; its sales show adoption among adults with previously treated advanced melanoma.
Immunocore depends on Bristol-Myers Squibb Co. to supply nivolumab for its registrational Phase 3 trial combining that medicine with brenetafusp in first-line advanced cutaneous melanoma. Immunocore sponsors and funds the trial, while the medicine supplier receives no payment under the agreement; continued nivolumab supply is the link to watch.
Xencor, Inc. competes with Immunocore by developing medicines that bring T cells to solid tumors, using engineered antibodies rather than Immunocore’s T-cell-receptor approach. Xencor earns payments and potential royalties from partners that license its candidates; its solid-tumor bispecific trial progress is the more direct signal for Immunocore’s competitive landscape.
Bristol-Myers Squibb Co. earningsBMY
Bristol Myers Squibb’s report may indicate whether nivolumab remains available for the key Phase 3 trial of Immunocore’s brenetafusp combination.
Look for any mention of nivolumab production, supply or constraints. Continued availability would support Immunocore’s ability to run the trial it sponsors and funds; a shortage or uncertainty would put a key trial medicine at risk, but BMY’s report alone would not establish a change in Immunocore’s actual supply.
Delcath Systems Inc earningsDCTH
Delcath Systems’ report will show whether HEPZATO KIT is gaining U.S. sales, a signal of demand for another treatment among some uveal-melanoma patients, though its eligible patients do not fully overlap with KIMMTRAK’s.
Look at HEPZATO KIT sales and what Delcath says about patient uptake. Rising sales and broader uptake would show that some eligible patients are choosing this option, adding another treatment to the market Immunocore serves; weak sales would point to limited commercial pull. Because eligibility differs, this is not a direct measure of KIMMTRAK sales.
Immunocore Holdings plc earningsThis company
Immunocore earns its revenue from KIMMTRAK, and this report will show whether sales are expanding enough to narrow the company’s operating loss.
Read the change in KIMMTRAK sales alongside operating expenses and operating loss, and see whether sales grow in the United States, Europe and other markets. Growth across several markets with a narrower loss would show that commercial expansion is beginning to absorb ongoing costs; growth concentrated in a few markets, or higher sales without a narrower loss, would leave the breadth of expansion or cost control in question.
Replimune Group, Inc. earningsREPL
Replimune’s report will show whether its RP2 uveal-melanoma trial is advancing toward registration, a step toward a potential future alternative to KIMMTRAK.
Look for updates on RP2 trial progress and its path toward registration. Movement toward a registration decision would make a future treatment competing for uveal-melanoma patients more plausible; a stalled or unclear path would leave that competition more distant. Replimune has no approved products or product-sale revenue, so its report is not a comparison with current KIMMTRAK sales.
